FY2024 EPS Estimates for Cingulate Lifted by Zacks Small Cap

Cingulate Inc. (NASDAQ:CING) – Zacks Small Cap increased their FY2024 earnings per share estimates for Cingulate in a research note issued on Tuesday, November 12th. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings of ($9.50) per share for the year, up from their prior estimate of ($16.00). The consensus estimate for Cingulate’s current full-year earnings is ($9.26) per share. Zacks Small Cap also issued estimates for Cingulate’s Q4 2024 earnings at ($1.49) EPS, FY2025 earnings at ($2.33) EPS and FY2026 earnings at ($0.27) EPS.

Cingulate (NASDAQ:CING) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.22) by $0.39.

Cingulate Price Performance

CING opened at $4.20 on Thursday. Cingulate has a 1 year low of $1.80 and a 1 year high of $152.40. The stock has a fifty day moving average price of $4.70 and a 200 day moving average price of $3.05.

Institutional Trading of Cingulate

An institutional investor recently bought a new position in Cingulate stock. Armistice Capital LLC purchased a new position in Cingulate Inc. (NASDAQ:CING) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 490,000 shares of the company’s stock, valued at approximately $157,000. Armistice Capital LLC owned about 6.67% of Cingulate at the end of the most recent reporting period. 41.31% of the stock is currently owned by hedge funds and other institutional investors.

Cingulate Company Profile

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.